Fabasoft AG

  • WKN: 922985
  • ISIN: AT0000785407
  • Land: Austria

Nachricht vom 27.08.2021 | 07:50

Fabasoft AG - figures for the first three months of the fiscal year 2021/2022 at a glance

DGAP-News: Fabasoft AG / Key word(s): Quarterly / Interim Statement
27.08.2021 / 07:50
The issuer is solely responsible for the content of this announcement.

Fabasoft AG (ISIN AT0000785407, WKN 922985, Prime Standard) announced on
27 August 2021 Group figures for the first three months of the fiscal year 2021/2022
(01/04/2021-30/06/2021):

- Sales revenue: EUR 13.6 million (EUR 14.3 million in the first three months of the fiscal year 2020/2021)
- EBITDA: EUR 3.9 million (EUR 5.9 million in the first three months of the fiscal year 2020/2021)
- EBIT: EUR 2.4 million (EUR 4.5 million in the first three months of the fiscal year 2020/2021)
- Cash flows from operating activities: EUR 0.5 million (EUR 4.4 million in the first three months of the fiscal year 2020/2021)
- Cash and cash equivalents: EUR 37.0 million as of 30 June 2021 (EUR 44.0 million as of 30 June 2020)

Please access the report via the following links:
German: https://www.fabasoft.com/group/Fabasoft_AG_3_Monatsbericht_2021_2022.pdf
English: https://www.fabasoft.com/group/Fabasoft_AG_3_Monthsreport_2021_2022.pdf

Fabasoft is a European software manufacturer and provider of cloud services. Fabasoft's software products and cloud services ensure the consistent capture, organisation, secure storage and context-sensitive finding of all digital business documents as well as the media-neutral multichannel publishing of digital contents (www.fabasoft.com).

Fabasoft AG (ISIN AT0000785407; WKN 922985; Bloomberg Code FAA GY; Reuters Code
FAAS.DE)
Linz, 27 August 2021
Leopold Bauernfeind, Member of the Managing Board
E-mail: Leopold.Bauernfeind@fabasoft.com, Telephone: +43 732 60 61 62



27.08.2021 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de



show this

GBC im Fokus

IGEA Pharma N.V. Realignment to CBD extraction

The goal is to become the quality and cost leader in the field of CBD in Europe. To this end, a GMP pharma compliant plant is being built in Switzerland. The supercritical CO2 extraction process is to be used to achieve the highest standard of quality. The CBD market is growing strongly and with the focus on quality leadership and pure extraction, IGEA Pharma's new business model should be able to occupy an attractive niche market. With the proprietary supercritical CO2-extraction technology, other markets such as vanilla, rose or rosemary can be developed in the medium term. Based on our DCF model, we have determined a fair value of € 1.05 (CHF 1.13) per share and assign a BUY rating.

Aktuelle Research-Studie

International School Augsburg -ISA- gemeinnützige AG

Original-Research: International School Augsburg -ISA- gemeinnützige AG (von GBC AG): GBC Vorstandsinterview

29. November 2021